Advertisement
U.S. markets close in 3 hours 24 minutes

Crossject Société Anonyme (ALCJ.PA)

Paris - Paris Delayed Price. Currency in EUR
2.0150+0.0370 (+1.87%)
At close: 05:17PM CET
Full screen
Previous Close1.9780
Open1.9900
BidN/A x N/A
AskN/A x N/A
Day's Range1.9700 - 2.0150
52 Week Range1.5200 - 5.9600
Volume22,544
Avg. Volume70,355
Market Cap82.918M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.2500
Earnings DateSep 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.30
  • GlobeNewswire

    Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions

    Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions. Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem.Study underscores ZENEO® Midazolam’s usability in extreme, high-risk

  • GlobeNewswire

    Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

    Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafterCrossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject (IS